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Abstract
Background and Objective As pazopanib plasma trough concentrations are correlated with treatment outcome, we explored 
whether single nucleotide polymorphisms in the elimination pathway of pazopanib affect systemic pazopanib concentrations.
Methods The decreased function alleles CYP3A4 15389 C > T (*22), ABCB1 3435 C >T, ABCG2 421 C >A, and ABCG2 
34G >A were analyzed within a recently developed population-pharmacokinetic model.
Results Incorporation of CYP3A4*22 in the model resulted in a 35% lower clearance for variant carriers (0.18 vs. 0.27 
L/h; difference in objective function value: − 9.7; p < 0.005). Simulated median trough concentrations of cancer patients 
with CYP3A4*22 with 600 mg once daily or 800 mg once daily were 31 and 35 mg/L, respectively. The simulated trough 
concentrations for the population excluding the CYP3A4*22 carriers after 600 mg once daily or 800 mg once daily were 18 
and 20 mg/L, respectively.
Conclusion This analysis shows that CYP3A4*22 heterozygotes have a substantial lower pazopanib clearance and that dose 
adjustments based on CYP3A4*22 status could be considered.
This work was presented in part at the 2017 ESMO (European 
Society for Medical Oncology) Annual Meeting, Madrid, Spain 
(8–12 September, 2017), #607.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-018-0719-5) contains 
supplementary material, which is available to authorized users.
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Key Points 
Patients carrying CYP3A4*22 have a lower pazopanib 
clearance than CYP3A4 wild types.
In our simulations, a pazopanib dose of 600 mg in these 
patients leads to equal pazopanib exposure as wild type 
patients dosed at 800 mg.
This knowledge may potentially lead to alternative dos-
ing of patients carrying CYP3A4*22.
1 Introduction
Pazopanib is a tyrosine kinase inhibitor that is currently a 
first-line treatment option for renal cell carcinoma, and a sec-
ond-line treatment or beyond for non-adipocytic soft-tissue 
sarcoma [3, 4]. Despite its proven clinical efficacy in these 
tumor types, dosing may be a challenge, as toxicity may 
become a serious limitation: 14–15% of patients discontinue 
pazopanib because of adverse events [3, 4]. Nausea, diar-
rhea, headache, hand-foot skin reaction, fatigue, and liver 
function disorders are among the most common side effects. 
From the outset, it is unknown which patients will develop 
side effects and which patients will not.
Likewise, it cannot be predicted which cancer patients 
will benefit from treatment with pazopanib. There are many 
factors that determine the outcome of an individual patient 
to a particular treatment; the pharmacology of an anti-tumor 
drug being one of these. As trough concentrations below 
20.5 µg/mL have been associated with a worse clinical out-
come [5, 6], it seems vital to dose patients up to this thresh-
old value. Recently, we showed that this strategy is feasible 
and does not lead to increased toxicity in most patients [7]. 
However, toxicity is dose limiting in a substantial number 
of patients, and may be the result of high systemic concen-
trations [8].
Several factors have been described to influence pazo-
panib exposure. Its absorption has been shown to increase 
with concomitant food intake [9, 10] and to decrease 
when stomach pH is reduced [11], whereas its elimination 
is known to be increased as a result of cytochrome P450 
(CYP)3A4 induction by ifosfamide or aprepitant [2, 12]. 
Although these drugs are generally not being used in com-
bination with pazopanib, these drug–drug interactions stress 
the importance of the function of the enzyme CYP3A4. 
However, drug transporters such as ABCB1 (P-glycopro-
tein) and ABCG2 (breast cancer resistant protein), for which 
pazopanib is a substrate, may also be relevant according to 
the summary of product characteristics.
Transporter and enzyme function are not solely 
affected by co-medication, but also by single nucleotide 
polymorphisms (SNPs) in their encoding genes. Up till 
now, genetic polymorphisms have been associated only 
with pazopanib pharmacodynamics rather than with its 
pharmacokinetics [13, 14]. Therefore, in the current 
study, it was our goal to associate four potentially relevant 
SNPs in CYP3A4, ABCB1, and ABCG2 with pazopanib 
pharmacokinetics. These SNPs have earlier been shown to 
be associated with the exposure of other tyrosine kinase 
inhibitors such as sunitinib [15]. We did this by imple-
menting SNP data into a recently developed population-
pharmacokinetic model for pazopanib systemic exposure, 
describing the complex metabolism of pazopanib in can-
cer patients [16].
2  Methods
2.1  Study Population
Patients were selected from three separate studies in which 
pazopanib pharmacokinetics had been assessed: two stud-
ies assessed the pharmacokinetic and pharmacodynamic 
drug interactions between pazopanib and either docetaxel 
(NTR2309) [1] or ifosfamide (NTR2063) [2] and the 
third study investigated the feasibility of therapeutic drug 
monitoring in pazopanib-treated patients (NTR3293) [17]/ 
Respectively 40, 41, and 13 patients were included in these 
studies. All patients signed informed consent.
2.2  Single Nucleotide Polymorphism Selection
As pazopanib is acknowledged as a substrate for CYP3A4, 
ABCB1, and ABCG2, four SNPs in the encoding genes 
for these proteins were selected, based on previous stud-
ies investigating other tyrosine kinase inhibitors [18–21]. 
Details of the investigated SNPs are depicted in Table 1.
2.3  DNA Isolation
If available, 2 mL of plasma or 3 mL of whole blood, stored 
at − 20 °C, was extracted on the MagNAPure Compact 
instrument (Roche Diagnostics GmbH, Mannheim, Ger-
many) using the Nucleic Acid Isolation Kit I (Roche Diag-
nostics GmbH) and a final elution volume of 200 μL.
2.4  Taqman® Genotyping
Predesigned drug-metabolizing enzymes  (Taqman® allelic 
discrimination assays) were used to perform genotyping 
on the Life Technologies  Taqman® 7500 system (Applied 
Biosystems, Life Technologies Europe BV, Bleiswijk, The 
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Netherlands). Each assay consisted of two allele-specific 
minor groove-binding probes, labeled with the fluorescent 
dyes VIC and FAM. Polymerase chain reactions were per-
formed in a reaction volume of 10 μL, containing assay-spe-
cific primers, allele-specific  Taqman® minor groove-binding 
probes, Abgene Absolute QPCR Rox Mix (Thermo Scien-
tific, Life Technologies Europe BV, Bleiswijk, The Neth-
erlands), and genomic DNA (20 ng). The thermal profile 
consisted of 40 cycles of denaturation at 95 °C for 20 s and 
annealing at 92 °C for 3 s and extension at 60 °C for 30 s. 
Allele-specific fluorescence was measured using the 7500 
software Version 2.3 for allelic discrimination (Applied Bio-
systems) to score genotypes.
2.5  Population‑Pharmacokinetic Model
A previously developed population-pharmacokinetic model 
with pharmacokinetic data from the same patients was used 
as a base model for the current analysis [16]. This model 
described the complex pazopanib pharmacokinetics includ-
ing the saturable absorption process and the drug–drug 
interaction with ifosfamide [22]. The remaining unexplained 
variation in pazopanib pharmacokinetics was predomi-
nantly reflected in the between-subject variability of the fast 
absorption rate constant (coefficient of variation = 140%) 
and clearance (coefficient of variation = 30.9%).
2.6  Statistical Analysis
All SNPs were in Hardy–Weinberg equilibrium. The genetic 
data were added to the data used for developing the pharma-
cokinetic model. NONMEM (Version 7.2; ICON, Ellicott 
City, MD, USA) with the first-order conditional estimation 
method with interaction was used for parameter estimation. 
Piraña was used as the modeling environment [23] and R 
(Version 3.3.1) was used for graphical interpretation of the 
data.
Genotypes with a frequency of more than 5% were tested 
in the base model and genotypes with a frequency of less 
than 5% were ignored. Covariates were included as dichoto-
mous covariates using the following equation:
where Ppop is the pharmacokinetic parameter of interest, pg 
was scored ‘1’ for patients of whom the genotype of inter-
est was present and ‘0’ for patients of whom the genotype 
was absent, θx is the typical parameter value of the wild-
type population, and θy is the covariate effect size estimate. 
The association of the SNPs with pazopanib clearance and 
bioavailability was investigated following a stepwise pro-
cedure. The potential association of all SNPs was univari-
ately tested for both pharmacokinetic endpoints. Univariate 
forward inclusion was performed using a p value of < 0.05 
as statistically significant (likelihood ratio test; 1 degree of 
freedom, difference in objective function value: 3.84). This 
was followed by a backward elimination procedure using a 
p value of < 0.005 (difference in objective function value: 
7.88) as the significance threshold (likelihood ratio test).
Ultimately, the final population-pharmacokinetic model 
[see Electronic Supplementary Material (ESM)] was used 
for simulating median trough concentrations for patients 
with and without CYP3A4*22 dosed at 400, 600, and 
800 mg once daily. For each combination of dose and geno-
type, 500 individuals were simulated. The simulated results 
were analyzed using R to present a concentration–time 
curve at steady state (6 weeks after start) and to calculate 
the percentage of simulated individuals reaching the target 
trough concentration of 20.5 ug/L. Goodness-of-fit plots are 
depicted in Fig. 1 of the ESM for all patients and in Fig. 2 of 
the ESM for the CYP3A4*22 carriers. 
3  Results
3.1  Patients
From the 96 patients in the original population-pharmacoki-
netic model by Yu et al. [16], germline DNA was genotyped 
successfully in 94 (98%) of them. From these 94 patients, 
761 samples had been drawn for pharmacokinetic analysis. 
Because most patients had participated in phase I studies in 
P
pop
= 휃x ×
(
휃y
)pg
,
Table 1  Investigated single nucleotide polymorphisms
MAF minor allele frequency, var variant, WT wild type
a MAF in this study
b MAF in Europeans (obtained from the 1000 Genomes Project Phase 3 Browser at www.1000g enome s.org on 26 March, 2018)
Gene rs number Allele Annotation WT/WT WT/var Var/var Missing MAFa (%) MAFb (%)
ABCG2 rs2231142 421C>A 75 18 1 0 11 9
ABCG2 rs2231137 34G>A 83 10 0 1 5 6
ABCB1 rs1045642 3435C>T 15 50 29 0 43 48
CYP3A4 rs35599367 15389C>T *22 83 11 0 0 6 5
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which pazopanib was combined with either ifosfamide or 
docetaxel, tumor types varied widely between patients and 
were therefore not recorded in this study. Pazopanib starting 
dose ranged from 200 to 1000 mg daily. Most patients were 
male (71%) and Caucasian (97%; Table 2).
3.2  Effect of Single Nucleotide Polymorphisma 
on Clearance and Bioavailability
Genotyping details are shown in Table 1. A planned back-
wards elimination procedure was not performed because 
only a single association was found to be significantly 
associated with an endpoint in the primary univariate tests; 
incorporation of CYP3A4*22 in the model resulted in a 35% 
lower clearance for variant carriers (0.18 vs. 0.27 L/h; differ-
ence in objective function value: – 9.47; p = 0.002). Effects 
of the other four SNPs on clearance and bioavailability are 
presented in Table 3.
Incorporation of the CYP3A4*22 in the model (Fig. 1) 
slightly reduced the inter-individual variability in clearance 
from 31 to 27%. Parameter estimates and between-subject 
variability of other pharmacokinetic parameters remained 
largely unaffected (Table 4).
Fig. 1  Schematic overview of the pazopanib (pazo) pharmacokinetic 
model [16]. ALAG lag time, CL clearance, fr fraction of pazopanib, 
KaF fast absorption rate constant, KaS slow absorption rate constant, 
Vc central volume of distribution, Vp peripheral volume of distribu-
tion
Fig. 2  Median simulated pazopanib trough concentration after a sin-
gle dose at steady state. The red line and the red dashed line represent 
the simulated concentration–time curves for CYP3A4*22 patients, 
treated with 800 mg and 600 mg of pazopanib daily, respectively. The 
black line and the black dashed line represent the simulated concen-
tration–time curve for wild-type (WT) patients for CYP3A4, treated 
with 800 mg and 600 mg of pazopanib daily, respectively. 1dd once 
daily
Table 2  Patient characteristics
IQR inter-quartile range, QD quoque dies (once daily), TDM thera-
peutic drug monitoring
Characteristics No. of patients (%)
Original study
 Pazopanib TDM [17] 13 (14)
 Phase I with docetaxel [1] 40 (43)
 Phase I with ifosfamide [2] 41 (44)
Sex
 Male 67 (71)
 Female 27 (29)
Age, y, median (IQR) 57 (48–64)
Pazopanib starting dose (mg QD)
 200 18 (19)
 400 38 (40)
 600
 800
3 (3)
20 (21)
 1000 15 (16)
Ethnicity
 Caucasian 91 (97)
 Asian 2 (2)
 Black 1 (1)
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To translate our findings to clinical practice, the final 
model (including CYP3A4*22) was used for the simulation 
of several dosing regimens for CYP3A4*22 carriers. Next, 
we compared these with the 600- and 800-mg once-daily 
dose for non-carriers. The median trough concentrations for 
the CYP3A4 wild-type population after 400, 600, or 800 mg 
Table 3  Effects of genotypes on parameter estimates
CL clearance, F bioavailability, ΔOFV difference in objective function value, PK pharmacokinetic, RSE relative standard error, var variant, WT 
wild type
a NONMEM run unsuccessful because of rounding errors
Factor Compared genotypes PK parameter Parameter estimate (RSE %) p value (ΔOFV)
ABCG2 421C > A WT/WT vs. other F
CL
Other: F *1.02
WT/WT: 0.27 L/h, other: 0.28 L/ha
0.78 (0.08)
0.67 (0.18)a
ABCG2 34G >A WT/WT vs. WT/var F
CL
WT/var: F *1.24
WT/WT: 0.27 L/h, WT/var: 0.26 L/h
0.17 (1.87)
0.86 (0.03)
ABCB1 3435C >T WT/WT vs. other F
CL
Other: F *1.17a
WT/WT: 0.28 L/h, other: 0.27 L/h
0.21a (1.58)
0.64 (0.22)
ABCB1 3435C >T var/var vs. other F
CL
Var/var: F*1.01
Var/var: 0.28 L/h, other: 0.25 L/h
0.89 (0.02)
0.40 (0.71)
CYP3A4*22 WT/WT vs. WT/var F
CL
Var: F*0.81
WT/WT: 0.27 L/h (23%), WT/var: 0.18 L/h 
(17%)
0.16 (2.00)
0.002 (9.47)
Table 4  Parameter estimates of 
pazopanib
CV coefficient of variation, RSE relative standard error
Parameters Unit Base model esti-
mate [RSE (%)] 
[16]
Final model 
estimates [RSE 
(%)]
Fast absorption rate constant h−1 0.38 (32) 0.39 (23)
Slow absorption rate constant h−1 0.12 (28) 0.12 (28)
Fraction of fast absorption % 35 (34) 36 (36)
Fraction of slow absorption % 65 (34) 64 (36)
Lag time between fast and slow absorption h 0.98 (6) 0.97 (6)
Clearance L/h 0.27 (23) 0.28 (23)
Clearance CYP3A4*22 L/h 0.18 (18)
Volume of distribution of central compartment L 2.39 (35) 2.4 (34)
Inter-compartment clearance L/h 0.99 (29) 0.97 (29)
Volume of distribution of peripheral compartment L 25.3 (27) 24.3 (28)
Dose level with half of bioavailability at dose 200 mg mg 478 (23) 466 (23)
Magnitude of decrease in relative bioavailability in time % 49.7 (27) 51 (27)
First-order decay constant Day−1 0.15 (44) 0.16 (44)
Between-subject variability
 Fast absorption rate constant CV% 142 (20) 142 (20)
 Clearance CV% 31 (20) 27 (28)
 Volume of distribution of peripheral compartment CV% 98 (17) 98 (18)
 Relative bioavailability CV% 36 (16) 38 (15)
Within-subject variability
 Relative bioavailability CV% 74 (22) 76 (22)
Residual unexplained variability
 Proportional residual error CV% 8.0 (6) 8.0 (11)
 Additive residual error mg/L 3.0 (26) 2.91 (27)
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once daily were 16, 18 and 20 mg/L, respectively (Fig. 2; 
Table 1 of the ESM). The median trough concentrations for 
the CYP3A4*22 heterozygotes with 400, 600, or 800 mg 
once daily were 27, 31, and 35 mg/L, respectively.
4  Discussion
In the current analysis, we found that CYP3A4*22 is asso-
ciated with a significantly lower pazopanib clearance. Our 
simulations estimate that trough concentrations at steady 
state are more than 50% higher for these patients, com-
pared with patients who are wild type for this gene. This 
percentage is deemed clinically relevant, as this is not an 
uncommon mutation in the European population (minor 
allele frequency 5% [24]) and CYP3A4*22 carriers could 
be more prone to develop toxicity compared with wild-
type patients.
Five years previously, it was shown that CYP3A4*22 is 
associated with a lower expression of the CYP3A4 enzyme, 
which resulted in decreased CYP3A4-dependent activity 
in the liver [25]. This reduced CYP3A4 activity has been 
shown to be associated with altered pharmacokinetics of 
several drugs, e.g., tacrolimus, midazolam, and erythro-
mycin [26], and to be associated with an increased risk of 
side effects with for example, cyclosporine and paclitaxel 
[27, 28]. Furthermore, the clearance of sunitinib, another 
vascular endothelial growth factor receptor tyrosine kinase 
inhibitor, was found to be approximately 23% lower in 
CYP3A4*22 carriers [15]. In transplant patients, for whom 
it is important to quickly dose optimally to prevent organ 
rejection, this SNP has been used to predict tacrolimus expo-
sure and to adjust its starting dose depending on the geno-
type [29, 30]. In contrast, in drugs that are also metabolized 
by CYP2D6, such as tamoxifen and several antipsychotics, 
CYP3A4*22 appears to be of less importance [31, 32].
The investigated SNPs in ABCB1 and ABCG2 were not 
significantly associated with pazopanib bioavailability or 
clearance, although both proteins encoded by these genes 
are located on intestinal enterocytes and on hepatocytes. 
Possibly, the full contribution of these transporters to paz-
opanib pharmacokinetics is not covered by the selected 
polymorphisms or is not reflected by bioavailability or 
clearance. However, given the fact that little to no litera-
ture on these transporters and pazopanib pharmacokinetics 
is available, apart from the summary of product charac-
teristics, it is likely that their contribution to pazopanib 
pharmacokinetics is rather small.
Given the limited number of investigated patients in our 
study, only a few SNPs could be selected to have sufficient 
statistical power for the analyses. Although the analyses 
might therefore have not been comprehensive, we deemed 
that the investigated SNPs were the most likely candidates 
to cause relevant pharmacokinetic alterations, based on 
the currently available literature. As reported previously 
[16], bootstrapping is not a suitable method for validating 
this model given its complexity and the different sampling 
schedules used.
Furthermore, clinical outcome (i.e., toxicity and survival) 
was not assessed in this analysis. As the pharmacokinetic 
data were collected from different phase I and pharmacoki-
netic studies, the study population was largely heterogeneous 
regarding confounding factors such as pazopanib dose, tumor 
type, disease stage, and concomitant (anti-cancer) medication. 
These factors should be taken into account to determine true 
effects on clinical outcome. The effect of CYP3A4*22 on the 
effect of pazopanib therefore remains to be investigated further 
in prospective clinical trials, but our simulations show that a 
dose reduction to 600 mg daily in CYP3A4*22 carriers pro-
vided even higher pazopanib trough concentrations than the 
approved 800-mg dose in wild-type patients, which potentially 
makes them more susceptible to toxicity.
5  Conclusion
CYP3A4*22 carriers have a significantly reduced pazopanib 
clearance, which potentially makes them more susceptible to 
(severe) toxicity. Simulations suggest that dosing these patients 
at pazopanib 600 mg daily leads to adequate pazopanib trough 
concentrations, higher than those in wild-type patients dosed at 
800 mg daily. Future studies should investigate whether dose 
reductions also lead to less toxicity, without compromising the 
anti-cancer effect in this specific group of patients.
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